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Background: The purpose of this study was to evaluate HPV-DNA and p16INK4a (p16) expression as prog-
nostic markers for outcome in patients with anal cancer.
Methods: From January 2000 to December 2011 a cohort of 105 anal cancer patients was treated with
deﬁnitive chemoradiation at our institution. Tumor biopsies from 90 patients were analyzed for HPV-
DNA by polymerase chain reaction and for p16 expression by immunohistochemistry.
Results: Median follow-up was 48.6 months (range 2.8–169.1 months). HPV-DNA or p16-expression was
found in 75 anal cancers each (83.3%), concordance was detectable in 70 tumors (77.8%). Signiﬁcantly
improved overall survival (OS) [77.1% vs. 51.4%, p = 0.005], progression-free survival (PFS) [64.0% vs.
35.0%, p < 0.001] and improved local control [81.0% vs. 55.9%, p = 0.023] was found for concomitant
HPV- and p16-positive anal carcinomas (cHPPAC) in univariate analysis. Multivariate analysis showed
better OS [p = 0.015] and PFS [p = 0.002] for cHPPAC.
Conclusion: The combination of HPV-DNA and p16 can be used as an independent prognostic parameter
in anal cancer patients.
 2014 Elsevier Ireland Ltd. Radiotherapy and Oncology 113 (2014) 331–336 This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Anal squamous cell carcinoma (SCC) represents with an overall
incidence rate of 1.08/100,000 an uncommonmalignancy, but inci-
dence rates of 70/100,000 in HIV-positive men and an overall
increasing incidence over the past years highlight its medical
importance [1,2]. Therefore several studies are focusing on new
treatment approaches for patients with anal SCC, such as a possible
reduction of side effects by using vaginal dilators or intensity-mod-
ulated radiotherapy (IMRT) technology [3–6]. In this regard the
identiﬁcation of prognostic markers will be important.
Anal SCC display interesting etiological similarities to genital
and some oropharyngeal malignancies: several studies have shownassociations between anal cancer with human immunodeﬁciency
virus (HIV) and human papillomavirus (HPV) [7,8].
The contribution of HPV to cancers of various anatomic loca-
tions has attracted increasing interest with more data implying
an important clinical signiﬁcance. For oropharyngeal cancer
patients, HPV infection is a strong and independent prognostic fac-
tor for survival. Ang et al. have demonstrated that 3-year overall
survival (OS) was signiﬁcantly better (82.4% vs. 57.1%; p < 0.001)
for patients with HPV-positive oropharyngeal tumors than for
those without a detection of HPV [9]. The sole detection of HPV-
DNA bears the risk of misclassifying cancers as HPV-associated,
since it does not prove overexpression of the viral oncogenes and
consequently HPV-induced transformation. Therefore additional
biomarkers are studied to reﬁne the identiﬁcation of HPV-associ-
ated tumors with the goal of achieving a clinically acceptable
accuracy. In this regard, the cyclin-dependent kinase inhibitor 2A
(CDKN2A), better known as p16INK4a (p16), is considered as an
important marker. Controlled by the retinoblastoma gene product
pRB, p16 acts as a tumor suppressor protein by inhibiting the
G1-checkpoint regulatory cyclin-dependent kinases (CDK) -4 and
-6 [10–13]. In HPV-associated cancers however the viral
oncoprotein E7 indirectly substantially increases transcription of
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without tumor suppressive action.
Several studies demonstrate that overexpression of p16 allows
for precise identiﬁcation of HPV-associated transformation
[14,15]. Expression of p16 in squamous cell carcinoma of the phar-
ynx and supraglottic larynx was signiﬁcantly correlated with
improved 5-year locoregional tumor control (LC), disease-speciﬁc
survival (DSS) and OS (all: p < 0.001) [16]. Furthermore, there are
studies demonstrating a better prognostic stratiﬁcation of oropha-
ryngeal cancers by p16 and combined HPV/p16 testing compared
to HPV DNA alone [10,17].
The shared HPV-transforming phenotype of anal squamous cell
cancer (SCC) and oropharyngeal cancer suggests similar clinical
implications. Accordingly, patients with HPV-associated anal SCC
appear to have a better outcome than HPV-negative anal SCC
[18,19] – similar towhat has been shown for head and neck cancers.
However, thenumberof studies addressing theprognostic relevance
of HPV in anal SCC is still limited. Thus, the basis for prospective tri-
als adapting treatment protocols stratiﬁed by HPV status is not suf-
ﬁciently established yet. Particularly, the role of HPV and p16 and
combined detection in anal SCC is still under discussion [20].
With the present study, we aimed to investigate the impact of
tumor HPV status and p16 expression on clinical outcome of
patients with anal cancer treated with deﬁnitive chemoradiation.
Retrospective analysis was performed using a patient cohort
undergoing chemoradiation at our institution.Table 1





Age – median 55 years 56 years
(range) (28–94 years) (22–86 years)
Sex – % (n)
Female 92.0% (69) 53.3% (8)
Male 8.0% (6) 46.7% (7)Methods
Patients’ characteristics
From January 2000 to December 2011, 105 patients with histo-
logically proven anal cancer were treated with chemoradiation at
the Department of Radiation Oncology, University Hospital Heidel-
berg or at the German Cancer Research Center, Heidelberg. Tumor
tissue biopsies from 90 patients taken at the time of diagnosis were
available and could be included in the study. The biopsies were
retrieved as formalin-ﬁxed, parafﬁn-embedded tissue from local
pathologists and the Institute of Pathology of the University Hospi-
tal Heidelberg (Tissue Bank of the National Center for Tumor Dis-
ease (NCT), Heidelberg). Patients with palliative treatment or
recurrent disease were excluded. Tumor stage, details of chemora-
diation, follow-up exams and patient characteristics were obtained
from medical records. The study was granted ethical approval by
the local ethics committee Heidelberg.
The cohort of 90 patients with a median age of 55 years (range
22–94 years) was treated with radiochemotherapy or radiotherapy
alone. 77 (85.6%) patients were female, 13 (14.4%) were male. A
majority of patients (53.3%) showed tumor size from 2 to 5 cm,
typically without nodal involvement (75.5%). Four carcinomas
were located at the anal margin.T stage – % (n)
T1 17.3% (13) 20.0% (3)
T2 56.0% (42) 40.0% (6)
T3 18.7% (14) 20.0% (3)
T4 8.0% (6) 20.0% (3)
N stage – % (n)
N0 74.7% (56) 80.0% (12)
N1 6.6% (5) 13.3% (2)
N2 10.7% (8) 6.7% (1)
N3 8.0% (6) 0
Radiotherapy – median 54.0 Gy 54.0 Gy
(range) (45.0–63.0 Gy) (50.4–63.2 Gy)
Single fraction dose – median 2.0 Gy 2.1 Gy
(range) (1.8–2.2 Gy) (1.8–2.2 Gy)
Overall treatment time – median 36 days 36 days
Treatment break > 3 days (n) 8% (6) 6.7% (1)Treatment and follow-up
Patients were treated with 3D-conformal radiotherapy (35.6%)
or intensity-modulated radiotherapy (IMRT), either as step-and-
shoot-IMRT or helical tomotherapy (63.3%). One patient (1.1%)
received only electrons because of a small, superﬁcial lesion. The
median radiotherapy dose was 45.0 Gray (Gy) (range 36.0–
50.4 Gy) including the macroscopic tumor, bilateral iliac, inguinal
and pararectal lymph nodes. A sequential or simultaneous boost
on macroscopic tumor or involved lymph nodes was performed up
to a median total dose of 54.0 Gy (range 45.0 Gy–63.2 Gy). 76.7%
of all patients received chemotherapy with 5-ﬂuorouracil (5-FU)
1000 mg/m2 body surface (typically days 1–5 and 29–33) plus
mitomycin (MMC) 10 mg/m2 body surface (days 1 and 29). Adiscontinuation of chemotherapy after the ﬁrst cycle was necessary
because of fulminant side effects (e.g. thrombocytopenia) for 3
patients (3.3%). 18 patients (20.0%) with relevant comorbidities
(e.g. cardiac conditions) and/or poor Karnofsky performance score
received only radiotherapy, 3 patients (3.3%) received other types
of chemotherapy (Cisplatin + Etoposide, Cisplatin + 5-FU, 5-
FU + Carboplatin). Patient and treatment characteristics are listed
in Table 1.
Follow-up examinations were performed every 3–6 months for
a minimum of 3 years and then annually including physical exam-
ination, imaging (MRI or CT), rectoscopy and biopsy for abnormal
ﬁndings.HPV-DNA detection and genotyping
DNA extraction was performed using QIAGEN (Venlo, Nether-
lands) DNeasy Blood and Tissue Kit from the available, forma-
lin-ﬁxed and parafﬁn-embedded tissue sections. For polymerase
chain reaction (PCR) consensus HPV primers-sets (modiﬁed
GP5+6+) were used. PCR was performed with two positive controls
(‘‘CaSki’’ for HPV16, ‘‘HeLa’’ for HPV18) and one negative control
(water). After 40 cycles of nucleic acid ampliﬁcation, 10 lL of
ampliﬁed DNA were stained with GelRed™ and analyzed by aga-
rose gel electrophoresis. Samples with bands of about 150 base
pairs corresponding to the length of positive control amplicons
were considered positive.
We performed genotyping with positive samples using the Mul-
tiplex HPV Genotyping Kit from Multimetrix GmbH (Regensburg,
Germany, now DiaMex, Heidelberg, Germany) for subtypes HPV6,
HPV11, HPV16, HPV18, HPV26, HPV31, HPV33, HPV35, HPV39,
HPV42, HPV43, HPV44, HPV45, HPV51, HPV52, HPV53, HPV56,
HPV58, HPV59, HPV66, HPV68, HPV70, HPV73 and HPV82. All pro-
cedural steps and evaluation of the results were done according to
the manufacturer’s instructions. Samples were considered positive
– in accordance with the literature [21,22] – if median intensity of
ﬂuorescence in the Luminex Analyzer was 10 or higher and equal
or more than 70 beads could be counted.p16 immunohistochemistry
p16-immunohistochemistry was performed on 2 lm tissue sec-
tions using the CINtec p16INK4a-histology kit (mtm Laboratories,
S.A. Koerber et al. / Radiotherapy and Oncology 113 (2014) 331–336 333Heidelberg, Germany) according to the manufacturer’s instruc-
tions. p16 expression was detected with a monoclonal anti-human
p16INK4a antibody (E6H4™) and a secondary antibody conjugated
to horseradish-peroxidase allowing for 3,30-Diaminobenzidine
(DAB)-based visualization. Tissue sections with a diffuse tumoral
p16-staining variably reaching the entire tumor area as previously
published [23,24] were considered positive. Lesions showing either
a sporadic or focal staining were described as negative.Statistical analysis
All survival end-points were calculated starting from the ﬁrst
diagnosis date. OS was then deﬁned as the time to death from
any cause. LC was deﬁned as the time to locally progressive disease
of the primary tumor or regional lymph nodes. PFS and CFS were
deﬁned respectively as the time to progressive disease and the
time to colostomy or death. All patients who did not experience
an event at the last follow-up date were censored. In detail events
were death for OS, progressive disease or death for PFS, progressive
disease for LC, colostomy or death for CFS. To explore possible dif-
ferences between the HPV-positive group versus the HPV-negative
group, the p16-positive group versus the p16-negative group as
well as the group with concomitant HPV- and p16-positive anal
carcinomas (cHPPAC) versus the rest of the patients, the Fischer’s
exact test was applied. The Kaplan–Meier method was used to esti-
mate OS, PFS, CFS, and LC for various group partitions. Univariate
survival time comparisons were performed using the log-rank test.
Multivariate analyses were performed using Cox regression. The
statistical analysis was performed using R version 3.0.2.
Results
After a median follow-up of 48.6 months (range 2.8–
169.1 months) for the entire cohort, 20 patients (22.2%) had a local
relapse and 10 patients (11.1%) developed a systemic recurrence.
The 3-year progression-free survival (PFS), colostomy-free survival
(CFS) and overall survival (OS) rates were 63.3% (95% CI 54.1–
74.1%), 85.5% (95% CI 77.1–94.8%) and 77.3% (95% CI 69.0–86.6%),
respectively. The local control rate at 3 years was 76.4% (95% CI
67.8–86.0%).
75 patients (83.3%) had detectable HPV-DNA in the tumor spec-
imens. On immunohistochemistry, p16-positivity was found in 75
tumors (83.3%). 77.8% (70) tumors were positive for both, HPV-
DNA and p16. HPV-16 was the most frequently (92.0%) detected
genotype in our cohort (Table 2). Explorative analyses revealed
that gender was the only parameter signiﬁcantly associated with
both HPV- and/or p16-positivity (p < 0.001). Among female
patients, 90% had HPV-DNA-positive tumors whereas only 46% of
the male patients had evidence of HPV-DNA in the tumor specimen
(p < 0.001; explorative analysis). Patients with p16-positive tumors
had less advanced nodal disease (p = 0.035; explorative analysis).
Patients with HPV-DNA-positive tumors and with cHPPAC had a
signiﬁcantly better overall survival whereas p16-expression alone
conferred no signiﬁcant survival beneﬁt (Fig. 1). The actuarial over-
all survival rates for patients with HPV-DNA-positive and -negative
cancers were 75.8% (95% CI 65.7–87.5%) and 48% (95% CITable 2
HPV DNA genotype status of 90 tissue slides.
HPV genotype % (n)
HPV 16 92.0 (69)
HPV 18 4.0 (3)
HPV 33 1.3 (1)
HPV 45 1.3 (1)
HPV 51 1.3 (1)26.3–87.7%) (p = 0.007). For patients with cHPPAC, actuarial OS
was 77.1% (95% CI 66.7–89.0%) compared to 51.4% (95% CI 32.2–
82.2%) for patients with one or two negative parameters
(p = 0.005). For progression-free survival, similar results were
found (Fig. 2), although p16-expression was associated with a sig-
niﬁcant beneﬁt for this survival endpoint (p = 0.002). On univariate
analyzes also tumor stage and patient age (cut-off 65 years) were
related to signiﬁcantly better PFS and OS. In terms of local recur-
rence, patients with cHPPAC had a signiﬁcantly higher local control
than patients with one or both parameters being negative
(p = 0.023). In patients with HPV-DNA-positive tumors this ﬁnding
was only of borderline signiﬁcance (p = 0.051). Patients with HPV-
DNA-positive cancers had a signiﬁcantly lower risk for distant
recurrence (p = 0.005) while there was a strong trend toward bet-
ter distant control for patients with cHPPAC (p = 0.051). These
results were comparable when performing univariate analyzes
only with patients treated with chemoradiation (n = 72). PFS and
LC were signiﬁcantly better for cHPPAC patients (p = 0.005/0.02).
There was a trend toward better OS in patients with cHPPAC,
although this difference was not statistically signiﬁcant
(p = 0.07). Regarding systemic relapse only for HPV-DNA a statisti-
cally signiﬁcant difference was found (p = 0.03). On the other hand
large tumor volumes (T3, T4) had a signiﬁcantly worse OS
(p = 0.001), PFS (p = 0.03) and local control (p = 0.08) compared to
small tumor volumes (T1, T2). Systemic relapse showed no statis-
tically signiﬁcant difference between both subgroups.
To identify independent prognostic factors for PFS and OS, mul-
tivariate analyses were performed. In a multivariate model consist-
ing of patient age (with two patient groups, 6 or >65 years
respectively), concomitant HPV-DNA and p16-expression and
tumor stage (with T1– T2 vs. T3–T4 patient groups), both concom-
itant HPV-DNA and p16-expression (p = 0.002, HR 0.32) and
patient age (p = 0.026, HR 0.46) were proved to be independent
prognostic factors for PFS. Regarding OS the multivariate analyses
revealed that parameters ‘‘tumor stage’’ (p = 0.003, HR 4.03) and
‘‘coexistence of HPV-DNA and p16-expression’’ (p = 0.015, HR
0.33) emerged as signiﬁcant predictors. Finally, our multivariate
analysis for OS showed age to be a time-dependent covariate,
whose effect decreases with time. The results of univariate and
multivariate analyses for OS and PFS are summarized in Table 3.Discussion
The inﬂuence of tumor HPV-DNA and p16 status on outcome of
patients with anal SCC undergoing chemoradiation is still forming
the focus of several studies and was also discussed in the current
ESMO-ESSO-ESTRO clinical practice guidelines for anal cancer
[25]. A couple of analyses suggested a potential beneﬁt of both
parameters regarding OS and PFS [18,19,26], while others called
into question the prognostic role of HPV-DNA and p16 status
[27,28,20]. This inconsistency necessitates further work.
In the current study we analyzed HPV-DNA and p16-status in a
cohort of 90 patients with anal carcinoma treated with chemoradi-
ation at our institution and assessed the inﬂuence of HPV-DNA,
p16 and combined detection on patient’s outcome. Our results on
sole HPV-DNA positivity showed signiﬁcantly improved OS
(75.8% vs. 48%, p = 0.007) and PFS (63.5% vs. 26.7%, p < 0.001), con-
ﬁrming other studies: Serup-Hansen et al. reported better OS (74%
vs. 52%, p = 0.036) in HPV positive tumors of the anal canal com-
pared with malignancies without HPV-DNA detection [19]. These
results are in accordance with ﬁndings from head and neck squa-
mous cell carcinomas (HNSCC), where a difference in OS of 48%
(79% vs. 31%, p < 0.001) could be identiﬁed in a cohort of 111
patients with oropharyngeal carcinoma [29]. In a retrospective












































































Fig. 2. Progression-free survival for the entire cohort (left) and for anal carcinomas with both HPV-DNA- and p16-positivity (right).
334 Anal cancer and HPVchemoradiation the authors observed a signiﬁcantly improved 3-
year OS for HPV-positive tumors (82.4% vs. 57.1%, p < 0.001) [9].
p16-expression is used as a marker indicating the transforming
nature of HPV infections, by reﬂecting overexpression of the viral
oncogenes and not only presence of viral genomes (HPV DNA).
Although also the direct detection of viral oncogene transcripts
has been discussed to provide promising results in HNSCC
[30,31], immunohistochemical detection of p16 is technically easy
and widely used and its prognostic relevance in anal SCC should be
evaluated. Currently, there is only little data regarding p16 andanal SCC. In a cohort of 47 patients 4-year PFS was signiﬁcantly
better (p = 0.014) for patients with p16 positive tumors [18]. Sim-
ilar results were reported by Gilbert et al. with a signiﬁcantly
higher number of relapses and a worse OS (p < 0.001) for p16-neg-
ative anal cancer patients [26]. p16-expression conferred no statis-
tically signiﬁcant survival beneﬁt in our cohort (p = 0.06) whereas
we found improved PFS for p16 positive anal cancers (p = 0.001).
Since there was a trend favoring p16 positivity regarding OS in
our study, the number of analyzed biopsies (90 in our study, 47
in [18] vs. 153 in [26]) could explain the lack of signiﬁcance. Both
Table 3
Univariate and multivariate analyzes for OS and PFS.
Risk factor Univariate analysis (KM estimators) Multivariate analysis (Cox PH model)
% 95% CI P HR 95% CI P
OS
Sex
Female 73.4 (63.1; 85.3) 0.1012
Male 61.5 (40.0; 94.6)
Age, years
P65 38.0 (18.0; 80.4) 0.0072 1 0.7296*
<65 81.0 (71.7; 91.4) 1.329* (0.265, 6.658)*
HPV-status
Positive 75.8 (65.7; 87.5) 0.0069
Negative 48.0 (26.3; 87.7)
p16 status
Positive 74.1 (63.8; 86.1) 0.0610
Negative 60.0 (39.7; 90.7)
HPV & p16
Both positive 77.1 (66.7; 89.0) 0.0050 0.327 (0.133; 0.806) 0.01
Other 51.4 (32.2; 82.2) 1 51
T stage
T1–T2 80.1 (69.7; 91.9) 0.0013 1 0.0029
T3–T4 49.5 (31.6; 77.3) 4.027 (1.612; 10.057)
PFS
Sex
Female 59.8 (49.1; 72.8) 0.0814
Male 46.2 (25.7; 83.0)
Age, years
P65 30.0 (13.2; 68.1) 0.0424 1 0.0263
<65 65.5 (54.5; 78.6) 0.463 (0.235; 0.913)
HPV-status
Positive 63.5 (52.6; 76.8) <0.001
Negative 26.7 (11.5; 61.7)
p16 status
Positive 62.3 (51.4; 75.6) 0.0017
Negative 33.3 (16.3; 68.2)
HPV & p16
Both positive 64.0 (52.7; 77.7) < 0.001 0.323 (0.158; 0.659) 0.0019
Other 35.0 (19.3; 63.6) 1
T stage
T1–T2 62.6 (50.9; 77.0) 0.0283 1 0.1010
T3–T4 46.2 (30.5; 69.9) 1.8 (0.892; 3.633)
* Remark: These values correspond to the age effect as assumed to be time-independent. However, further analysis shows that age is in fact a time-dependent covariate,
with negative coefﬁcient for the time-age interaction (=0.0674). This interaction is statistically signiﬁcant with p = 0.0422. Our computations prove that the effect of age
declines with time: given that initially age has a positive effect on hazard (with the corresponding age-coefﬁcient = 0.2842), this effect decreases with time (at rate = 0.0674
per month) and becomes negative after about 5 months.
S.A. Koerber et al. / Radiotherapy and Oncology 113 (2014) 331–336 335the current and other mentioned studies used CINtec kits for p16
detection, which makes an inﬂuence of technical differences less
probable. However non-uniform interpretation of p16 expression
patterns as ‘‘positive’’ and different HPV prevalence may impact
the results.
Considering that p16 overexpression is not entirely restricted to
HPV-associated transformation, it may be important to analyze the
combined HPV-DNA-/p16-status in order to more speciﬁcally iden-
tify HPV-associated tumors. There is less data assessing the co-
detection of HPV-DNA and p16 expression regarding the outcome
of patients with anal carcinoma. However, that could be of interest
because several studies showed a clear beneﬁt by using a concom-
itant testing of HPV-DNA and p16 for HNSCC prognosis [32,33]. A
study conducted by Rödel et al. reported on decreased local failure
(p = 0.019) and improved cancer-speciﬁc (p = 0.04) and overall sur-
vival (p = 0.031) for anal cancer patients with high HPV16 DNA
load and p16 expression [34]. These results are in concordance
with our observations demonstrating improved OS (p = 0.005),
PFS (p < 0.001) and decreased local relapse rates (p = 0.023) for
patients with cHPPAC. In both studies there was no signiﬁcant rela-
tionship of concomitant HPV-DNA positivity and p16 expression
with the risk of developing distant metastases. This indicates that
the lack of local control could play an important role regarding
treatment of the other anal SCC subgroups.A comparison of all combined HPV-DNA- and p16- subgroups in
our cohort is limited due to the small numbers of patients with
HPV-DNA-negative p16-positive and HPV-DNA-positive p16-nega-
tive tumors. Nevertheless it is interesting to note that patients with
HPV-DNA-negative and p16-positive anal cancers tended to have
worse OS and PFS than the remaining three subgroups (data not
shown). If this ﬁnding can be conﬁrmed in larger studies, this
would be in conformity with ﬁndings from studies on oropharyn-
geal cancer [35,36]. However, other clinical analyses concluded
that patients with p16-positive, HPV-negative oropharyngeal
tumors are at similar risk as patients with p16-positive/HPV-posi-
tive tumors [37]. Anal SCC patients with detection of HPV-DNA and
no expression of p16 exhibited a worse OS but similar PFS com-
pared to HPV-DNA- and p16-positive tumors in our cohort (data
not shown). One might speculate that these tumors have no over-
expression of viral oncogenes and are therefore not attributable to
HPV.
The major limitation of our analysis is its retrospective nature.
We included a relatively high number of patients (n = 105) with
a long follow-up period (median 48.6 months) but prospective data
are necessary to conﬁrm our results.
In summary, concomitant detection of HPV-DNA and p16
expression represents a prognostic marker in patients with
anal carcinoma. Escalating treatment options for HPV- und
336 Anal cancer and HPVp16-negative tumors and de-escalating therapy for anal cancers
with HPV-DNA and p16 positivity could be considered with the
purpose of generating better outcome and less treatment-related
side effects. In this regard prospective trials are mandatory to fur-
ther determine the predictive role of HPV-DNA and p16 expression
in patients with anal cancer.Competing interests
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